Law360, Washington (January 24, 2012, 3:25 PM ET) -- Attorneys for three generic-drug makers on Tuesday urged the Federal Circuit to scrap an injunction barring them from selling a competing generic version of Momenta Pharmaceuticals Inc.’s blood-thinning drug generic of Sanofi SA's Lovenox in the U.S., saying substantial questions of law render the injunction erroneous.
In October, Momenta won a preliminary injunction blocking Watson Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc. and International Medical Systems Ltd. from selling their own version of Lovenox. The court found Momenta had shown a likelihood of success on the merits of...
Generics Cos. Fight Lovenox Injunction In Fed. Circ.
To view the full article, take a free trial now.
